Oculis Holding AG
Privosegtor
optic neuritis
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on Privosegtor for optic neuritis is in focus around Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“If the results are positive, we plan to submit a new drug application (“NDA”) to the FDA for OCS-01 for the treatment of DME in the fourth quarter of 2026.”